{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:52:23Z","timestamp":1791561143716,"version":"4.3.4"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>Background and Aims<\/jats:title>\n            <jats:p>Intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) are the most common primary liver cancers (PLCs). Differences in their clinical features and outcomes are open for investigation in a large\u2010scale study. We aim to investigate the differences in clinical features and outcomes between iCCA and HCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Approach and Results<\/jats:title>\n            <jats:p>The Surveillance, Epidemiology, and End Results Program 18 Database (2000\u20102017) was used to extract demographic and clinical features of HCC and iCCA patients. Logistic regression analysis was performed to identify factors associated with iCCA diagnosis versus HCC. Cox regression analysis was used to assess factors affecting overall survival (OS). There were 13,611 iCCA and 96,151 HCC patients. Half of iCCA (50.7%) and three quarters of HCC (76.3%) patients were male. Diagnosis in recent year, age (&lt;50 or \u226565), female sex, non\u2010Hispanic White race, higher income, rural area, and higher tumor burden were independently associated with iCCA diagnosis versus HCC. Patients with iCCA had worse OS than those with HCC (9 vs. 13\u00a0months; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;\u00a00.001). However, OS was comparable between iCCA and HCC in multivariable analysis (adjusted hazard ratio [aHR]\u00a0=\u00a01.02; 95% CI\u00a0=\u00a00.99\u20101.05). In subgroup analyses, iCCA was associated with better OS than HCC in patients with tumor \u22655\u00a0cm (aHR\u00a0=\u00a00.83; 95% CI\u00a0=\u00a00.80\u20100.86), lymph node involvement (aHR\u00a0=\u00a00.76; 95% CI\u00a0=\u00a00.72\u20100.81), distant metastasis (aHR\u00a0=\u00a00.76; 95% CI\u00a0=\u00a00.73\u20100.79), poorly\/undifferentiated tumors (aHR\u00a0=\u00a00.88; 95% CI\u00a0=\u00a00.83\u20100.94), and those receiving noncurative treatment (aHR\u00a0=\u00a00.96; 95% CI\u00a0=\u00a00.93\u20100.98).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We identified the demographic, socioeconomic, and clinical features associated with iCCA diagnosis over HCC among patients with PLC. Although iCCA patients presented at an advanced stage, OS was similar between iCCA and HCC in multivariable analysis. iCCA was associated with longer OS for subgroups with poor prognostic features.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.32007","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T06:35:47Z","timestamp":1623393347000},"page":"2622-2632","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":61,"title":["Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States"],"prefix":"10.1097","volume":"74","author":[{"given":"Yi\u2010Te","family":"Lee","sequence":"first","affiliation":[{"name":"California NanoSystems Institute,Crump Institute for Molecular Imaging,University of California\u2013Los Angeles,Los Angeles,CA"},{"name":"Department of Molecular and Medical Pharmacology,University of California\u2013Los Angeles,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine J.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Pharmacology,University of California\u2013Los Angeles,Los Angeles,CA"},{"name":"Samuel Oschin Comprehensive Cancer Institute,Cedars\u2010Sinai Medical Center,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Luu","sequence":"additional","affiliation":[{"name":"Biostatistics and Bioinformatics Research Center,Cedars\u2010Sinai Medical Center,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[{"name":"Karsh Division of Gastroenterology and Hepatology,Cedars\u2010Sinai Medical Center,Los Angeles,CA"},{"name":"Comprehensive Transplant Center,Cedars\u2010Sinai Medical Center,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas N.","family":"Nissen","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute,Cedars\u2010Sinai Medical Center,Los Angeles,CA"},{"name":"Comprehensive Transplant Center,Cedars\u2010Sinai Medical Center,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-9532","authenticated-orcid":false,"given":"Tushar C.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Mayo Clinic,Jacksonville,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis R.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Mayo Clinic,Rochester,MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Singal","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases,University of Texas Southwestern Medical Center,Dallas,TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Gores","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Mayo Clinic,Rochester,MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-9825","authenticated-orcid":false,"given":"Ju Dong","family":"Yang","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute,Cedars\u2010Sinai Medical Center,Los Angeles,CA"},{"name":"Karsh Division of Gastroenterology and Hepatology,Cedars\u2010Sinai Medical Center,Los Angeles,CA"},{"name":"Comprehensive Transplant Center,Cedars\u2010Sinai Medical Center,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"key":"hep32007-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability\u2010adjusted life\u2010years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study","volume":"3","year":"2017","journal-title":"JAMA Oncol"},{"key":"hep32007-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep32007-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep32007-bib-0004-20250824","first-page":"1073274817729245","article-title":"Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"24","year":"2017","journal-title":"Cancer Control"},{"key":"hep32007-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta\u2010analysis","volume":"72","year":"2020","journal-title":"J Hepatol"},{"key":"hep32007-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep32007-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta\u2010analysis","volume":"149","year":"2014","journal-title":"JAMA Surg"},{"key":"hep32007-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"hep32007-bib-0009-20250824","first-page":"437","article-title":"Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead\u2010transarterial chemoembolization and systemic chemotherapy","volume":"24","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep32007-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1245\/s10434-010-1333-4","article-title":"Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival","volume":"18","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"hep32007-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00270-011-0142-x","article-title":"Transarterial hepatic yttrium\u201090 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival","volume":"35","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"hep32007-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","article-title":"Yttrium\u201090 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option","volume":"17","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"hep32007-bib-0013-20250824","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"hep32007-bib-0014-20250824","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","year":"2002","journal-title":"Hepatology"},{"key":"hep32007-bib-0015-20250824","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","article-title":"Radioembolization results in longer time\u2010to\u2010progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma","volume":"140","year":"2011","journal-title":"Gastroenterology"},{"key":"hep32007-bib-0016-20250824","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00270-012-0481-2","article-title":"Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma","volume":"36","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"hep32007-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"hep32007-bib-0018-20250824","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3390\/cancers12082039","article-title":"Targeted therapies in advanced biliary tract cancer: an evolving paradigm","volume":"12","year":"2020","journal-title":"Cancers (Basel)"},{"key":"hep32007-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open\u2010label, phase 2 study","volume":"21","year":"2020","journal-title":"Lancet Oncol"},{"key":"hep32007-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1\u2010mutant advanced cholangiocarcinoma: a phase 1 study","volume":"4","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep32007-bib-0021-20250824","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1\u2010mutant, chemotherapy\u2010refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double\u2010blind, placebo\u2010controlled, phase 3 study","volume":"21","year":"2020","journal-title":"Lancet Oncol"},{"key":"hep32007-bib-0022-20250824","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"hep32007-bib-0023-20250824","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first\u2010line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non\u2010inferiority trial","volume":"391","year":"2018","journal-title":"Lancet"},{"key":"hep32007-bib-0024-20250824","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","year":"2020","journal-title":"N Engl J Med"},{"key":"hep32007-bib-0025-20250824","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"hep32007-bib-0027-20250824","first-page":"1","article-title":"mice: Multivariate Imputation by Chained Equations in R","volume":"45","year":"2011","journal-title":"J Stat Softw"},{"key":"hep32007-bib-0028-20250824","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","year":"1979","journal-title":"Scand J Stat"},{"key":"hep32007-bib-0029-20250824","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","year":"1994","journal-title":"Biometrika"},{"key":"hep32007-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"604","DOI":"10.5604\/01.3001.0012.0929","article-title":"Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States; 1995\u20102014","volume":"17","year":"2018","journal-title":"Ann Hepatol"},{"key":"hep32007-bib-0031-20250824","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/hep.31811","article-title":"State\u2010level hepatocellular carcinoma incidence and association with obesity and physical activity in the United States","volume":"74","year":"2021","journal-title":"Hepatology"},{"key":"hep32007-bib-0032-20250824","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11901-020-00554-6","article-title":"Racial and sex disparities in hepatocellular carcinoma in the USA","volume":"19","year":"2020","journal-title":"Curr Hepatol Rep"},{"key":"hep32007-bib-0033-20250824","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/jgh.15079","article-title":"Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus","volume":"35","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"hep32007-bib-0034-20250824","first-page":"163","article-title":"Socioeconomic status in HCV infected patients\u2014risk and prognosis","volume":"5","year":"2013","journal-title":"Clin Epidemiol"},{"key":"hep32007-bib-0035-20250824","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3748\/wjg.v19.i4.457","article-title":"Obesity and cholangiocarcinoma","volume":"19","year":"2013","journal-title":"World J Gastroenterol"},{"key":"hep32007-bib-0036-20250824","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41586-019-1171-x","article-title":"Rising rural body\u2010mass index is the main driver of the global obesity epidemic in adults","volume":"569","year":"2019","journal-title":"Nature"},{"key":"hep32007-bib-0037-20250824","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1001\/jama.2020.4501","article-title":"Trends in the prevalence of metabolic syndrome in the United States, 2011\u20102016","volume":"323","year":"2020","journal-title":"JAMA"},{"key":"hep32007-bib-0038-20250824","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1053\/j.gastro.2004.12.048","article-title":"Risk factors of intrahepatic cholangiocarcinoma in the United States: a case\u2010control study","volume":"128","year":"2005","journal-title":"Gastroenterology"},{"key":"hep32007-bib-0039-20250824","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41586-018-0519-y","article-title":"Necroptosis microenvironment directs lineage commitment in liver cancer","volume":"562","year":"2018","journal-title":"Nature"},{"key":"hep32007-bib-0040-20250824","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41575-018-0065-y","article-title":"Apoptosis and necroptosis in the liver: a matter of life and death","volume":"15","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep32007-bib-0041-20250824","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1042\/CS20140732","article-title":"Necroptosis is a key pathogenic event in human and experimental murine models of non\u2010alcoholic steatohepatitis","volume":"129","year":"2015","journal-title":"Clin Sci (Lond)"},{"key":"hep32007-bib-0042-20250824","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/MLR.0000000000000073","article-title":"Comparison of SEER treatment data with medicare claims","volume":"54","year":"2016","journal-title":"Med Care"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.32007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.32007","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/am-pdf\/10.1002\/hep.32007","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:09:38Z","timestamp":1756076978000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.32007","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"2021-02-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}